John F. Forbes

John F. Forbes's AcademicInfluence.com Rankings

John F. Forbes

Philosophy

#8099

World Rank

#11417

Historical Rank

Logic

#5130

World Rank

#6500

Historical Rank

philosophy Degrees

Download Badge

Philosophy

John F. Forbes's Degrees

Doctorate Medicine Stanford University

Why Is John F. Forbes Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John F. Forbes's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer (2005) (2258)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial (2002) (1902)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial (2013) (1615)
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. (2005) (1554)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. (2010) (1458)
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial (2005) (1219)
Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms (1998) (1048)
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials (2015) (934)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. (2007) (890)
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial (2007) (836)
Overview of the main outcomes in breast-cancer prevention trials (2003) (771)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. (2008) (687)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer (2003) (684)
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. (2010) (666)
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. (2011) (666)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (2015) (550)
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. (2010) (518)
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. (2007) (510)
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial (2014) (504)
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial (2010) (504)
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. (2009) (486)
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. (2010) (457)
Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients. (2006) (425)
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. (2015) (424)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. (2008) (420)
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data (2013) (398)
Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. (2011) (366)
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. (2011) (358)
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. (2016) (329)
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial (2015) (327)
Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. (1992) (322)
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received. (2010) (314)
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. (2010) (271)
A randomized trial comparing axillary clearance versus no axillary clearance in older patients (≥ 60 years) with breast cancer: First results of International Breast Cancer Study Group Trial 10-93. (2004) (259)
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. (2003) (254)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. (2013) (241)
Increased Hospital-Based Physical Rehabilitation and Information Provision After Intensive Care Unit Discharge: The RECOVER Randomized Clinical Trial. (2015) (234)
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A survival prediction model to facilitate clinical decision making. (2010) (213)
Preventive therapy for breast cancer: a consensus statement. (2011) (212)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. (2007) (193)
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. (2008) (181)
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. (2006) (178)
Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer (1996) (175)
Overview of the main outcomes in breast cancer prevention trials (2003) (170)
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. (2009) (161)
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. (2016) (157)
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial (2016) (150)
Displaced intracapsular hip fractures in fit, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty. (2005) (148)
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value (2015) (143)
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. (2006) (139)
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. (2008) (136)
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. (2011) (136)
The Cost of Stroke to the National Health Service in Scotland (1992) (133)
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. (2011) (133)
Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. (2010) (132)
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. (2011) (129)
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. (2007) (127)
A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial (2010) (119)
Health service costs and quality of life for early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms (1998) (118)
BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer (2005) (118)
The incidence of breast cancer: the global burden, public health considerations. (1997) (118)
Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomised controlled trial. (2014) (117)
Quality and the use of time in general practice: widening the discussion. (1989) (114)
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. (2011) (113)
Community-Based Stroke Incidence in a Scottish Population: The Scottish Borders Stroke Study (2005) (113)
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis. (2010) (112)
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. (2012) (108)
Restrictive Versus Liberal Transfusion Strategies for Older Mechanically Ventilated Critically Ill Patients: A Randomized Pilot Trial* (2013) (104)
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. (1995) (101)
Cost of Stroke (1993) (100)
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. (2011) (91)
Unemployment and mortality in post-war Scotland. (1984) (91)
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival (1998) (86)
Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer (2015) (83)
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial (2019) (83)
Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer (2014) (78)
Recommendations for collection and handling of specimens from group breast cancer clinical trials. (2008) (75)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC. (2009) (73)
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. (2007) (73)
Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes & Obesity in South Asians) (2011) (69)
The control of breast cancer: the role of tamoxifen. (1997) (68)
An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer (1997) (67)
The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. (1994) (64)
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: A description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification. (2010) (64)
The sequential use of endocrine treatment for advanced breast cancer: where are we? (2012) (63)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. (2013) (63)
Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. (1977) (63)
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. (2011) (61)
A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC) (2007) (60)
Breast cancer survivors. (2008) (59)
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93 (2008) (59)
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. (2007) (58)
Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. (2018) (58)
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. (2009) (55)
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. (2014) (55)
BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) (2007) (51)
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. (2012) (51)
INCREASED RISK OF BREAST CANCER AFTER LOW-DOSE IRRADIATION (1989) (50)
Risks of preterm delivery and small‐for‐gestational age infants following abortion: a population study (1985) (49)
Service provision for people with schizophrenia (1997) (48)
Systematic review of head cooling in adults after traumatic brain injury and stroke. (2012) (47)
Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. (2006) (46)
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer (2012) (45)
Timing breast cancer surgery (1991) (45)
Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11– (2001) (44)
Novel genes associated with lymph node metastasis in triple negative breast cancer (2015) (44)
Reproducibility of visual assessment on mammographic density (2008) (42)
Early elective open surgical repair of small abdominal aortic aneurysms is not recommended: results of the UK Small Aneurysm Trial. Steering Committee. (1998) (41)
Two sequential randomized trials of community participation to recruit women for mammographic screening. (1996) (40)
Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. (2009) (39)
BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. (2009) (38)
The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer (2014) (37)
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). (1998) (36)
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93 (2009) (35)
Symptoms of endocrine treatment and outcome in the BIG 1-98 study (2013) (35)
Predictive algorithms for adjuvant therapy: TransATAC (2011) (35)
Smoking, lung function and the prognosis of abdominal aortic aneurysm. The UK Small Aneurysm Trial Participants. (2000) (34)
Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I) (2017) (34)
Adjuvant ovarian function suppression and cognitive function in women with breast cancer (2016) (33)
DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients (2016) (32)
A randomised controlled trial evaluating a rehabilitation complex intervention for patients following intensive care discharge: the RECOVER study (2012) (31)
BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). (2006) (31)
Undergraduate education about cancer: a survey in Australian medical schools. (1988) (31)
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer (2015) (31)
Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options (2016) (31)
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer (2006) (30)
Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. (2006) (30)
Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial (2012) (28)
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. (2016) (28)
Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. (1997) (27)
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. (2012) (25)
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer (2004) (25)
A rehabilitation intervention to promote physical recovery following intensive care: a detailed description of construct development, rationale and content together with proposed taxonomy to capture processes in a randomised controlled trial (2014) (25)
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. (1996) (23)
Preventive dentistry in a health centre: effectiveness and cost. (1986) (22)
Resource use and costs of elective surgery for asymptomatic abdominal aortic aneurysm. (1997) (22)
Treatment and survival on advanced breast cancer. (1978) (22)
Perinatal mortality in Scotland: 1970-9. (1982) (21)
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II (2017) (20)
Influence of maternal age, parity and social class on perinatal mortality in Scotland: 1960–82 (1985) (20)
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer (2007) (19)
Improving informed consent in clinical trials: successful piloting of a decision aid. (2007) (19)
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. (2017) (19)
Long-term effects of adjuvant chemotherapy in breast cancer. (1992) (19)
Promotion of attendance for mammographic screening through general practice: a randomised trial of two strategies. (1992) (18)
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. (2016) (17)
Present and future projects of the international breast cancer study group (1994) (17)
10-year analysis of the ATAC trial: wrong conclusion? – Authors' reply (2011) (17)
Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. (2011) (17)
Male Unemployment and Cause-Specific Mortality in Postwar Scotland (1987) (16)
FAMILIAL MALE BREAST CANCER (1976) (16)
Principles and potential of palliative surgery in patients with advanced cancer. (1988) (16)
Design and baseline characteristics of the PODOSA (Prevention of Diabetes & Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes (2013) (16)
Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES). (2009) (14)
Economic aspects of health education. (1986) (14)
Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial. (2011) (13)
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study (2013) (13)
A classification of Scottish infants using latent class analysis. (1984) (13)
Is chemotherapy for non-small cell lung cancer worthwhile? (1993) (13)
Economic appraisal of preventive dental techniques. (1987) (13)
Towards an optimal teaching programme for supportive care (2004) (13)
Beneficial Effect of Tamoxifen for Women with DCIS: Long-Term Results from the UK/ANZ DCIS Trial in Women with Locally Excised DCIS. (2009) (12)
Prognostic value of performance status and quality-of-life scores during chemotherapy for advanced breast cancer. The Australian New Zealand Breast Cancer Trials Group. (1993) (12)
Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. (2010) (12)
Early breast cancer: Part I: Surgical pathology and preoperative assessment (1978) (12)
Exploring Decision‐Making about Neo‐adjuvant Chemotherapy for Breast Cancer (2016) (10)
Three Years' Follow-up from the ATAC Trial is Sufficient to Change Clinical Practice: A Debate (2004) (10)
Preconditioning Shields Against Vascular Events in Surgery (SAVES), a multicentre feasibility trial of preconditioning against adverse events in major vascular surgery: study protocol for a randomised control trial (2015) (10)
Treating Breast Cancer (2003) (10)
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. (2012) (10)
Early stopping of clinical trials (2005) (9)
Clinical trial of prophylaxis of wound sepsis in elective colorectal surgery comparing ticarcillin with tinidazole. University of Melbourne Colorectal Group. (1986) (9)
Clinical trial of prophylaxis of wound sepsis in elective colorectal surgery: Cephamandole with tinidazole versus tinidazole alone (1983) (9)
2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) (2007) (9)
Access to intensive neonatal care and neonatal survival in low birthweight infants: a population study in Norway. (1987) (9)
Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. (2013) (8)
Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference (2011) (8)
Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial. (2009) (7)
Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam). (2014) (7)
The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. (2006) (7)
Abstract P5-13-03: The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial (2010) (7)
Early breast cancer: Part II. Management (1978) (7)
0130 Initial adjuvant therapy with anastrozole - early- and late-event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population (2009) (7)
Risk Factors for Locoregional Recurrence Among Breast (2003) (7)
Adjuvant use of anastrozole in breast cancer. (2004) (7)
Pre-term Foetal Life Times in Scotland (1986) (6)
An analysis of bone scintigraphy in early (operable) breast cancer. (1979) (6)
Psychological treatment of phobic anxiety associated with adjuvant chemotherapy (1986) (6)
CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC). (2009) (6)
Laparoscopic exploration of intra- and extrahepatic bile ducts and T-tube drainage. (1995) (6)
The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies (2021) (6)
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference (2012) (5)
Aromatase inhibitors (AI) for elderly patients: Efficacy, compliance and safety according to patient age in the BIG 1–98 trial (2007) (5)
Education and palliative care: a different approach. (1991) (5)
Personalization of loco-regional care for primary breast cancer patients (part 2). (2015) (5)
Choosing between Endocrine Therapy and Chemotherapy – or is there a Role for Combination Therapy? (2002) (5)
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). (2014) (5)
Stress in General Medical Practitioners of the United Kingdom (1989) (5)
Personalization of loco-regional care for primary breast cancer patients (part 1). (2015) (4)
Correlation Between Nonspecific Immune Competence and Clinical Outcome of Breast, Colon, and Stomach Cancer (1979) (4)
Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trail (2005) (4)
Exploring decision making about neoadjuvant chemotherapy for early breast cancer. (2014) (4)
Monitoring distributional assumptions and early stopping for a prospective clinical trial using Monte Carlo simulation. (1987) (4)
BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. (2006) (4)
Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311 (2019) (3)
Association Between Walking Pace and Stroke Incidence (2020) (3)
Use of the pictorial Epworth Sleepiness Scale in adults with Down's syndrome (2012) (3)
The treatment of locally advanced breast cancer. A discussion document. (1980) (3)
Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1) (2008) (3)
Mammary serum antigen (MSA) in advanced breast cancer (1990) (3)
Risk-Targeted Selection of Agricultural Holdings for Post-Epidemic Surveillance: Estimation of Efficiency Gains (2011) (3)
Why costs of consultations in general practice vary. (1990) (3)
Drug resistance in clinical practice: patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer. (1987) (3)
Multimodality treatment of cancer. (1982) (3)
Abstract P3-07-02: Prognostic and predictive relevance of HER2 status in ductal carcinomain situ: Results from the UK/ANZ DCIS trial (2016) (2)
ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen--A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer. (2011) (2)
Treating Skin Cancer (2003) (2)
Timing of breast cancer surgery in the menstrual cycle and outcome. (1991) (2)
Economics of Prevention and Treatment (1991) (2)
PREVALENCE OF SLEEP-DISORDERED BREATHING IN ADULTS WITH DOWN'S SYNDROME IN SCOTLAND (2012) (2)
HIGHLIGHTS IN DEVELOPMENT OF RANDOMIZED CLINICAL TRIALS (1981) (2)
PI3 Kinase Pathway Analysis in Tissue Microarrays Using Laser Capture Microdissection and Immunohistochemistry. (2009) (2)
Effect of Body Mass Index on Recurrence in Hormone Receptor Positive Early Breast Cancer – A Retrospective Exploratory Analysis from the ATAC Trial. (2009) (2)
Public policy and primary medical care in the UK: an economic perspective on Promoting Better Health. (1988) (2)
Final analysis of a randomized comparison of letrozole (Let) vs observation (Obs) as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive (HR+) breast cancer (BC) after completion of prior AET: ANZBCTG 0501 (LATER). (2015) (2)
Primary Medical Care Financing and Physician Payment Systems: A European Perspective (1990) (2)
Abstract S3-01: Breast cancer prevention using anastrozole in postmenopausal women at high risk (2013) (2)
ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen-A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer. (2011) (2)
Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS) (2018) (2)
Abstract P1-12-06: Co-SOFT: The cognitive function substudy of the suppression of ovarian function trial (SOFT) (2015) (2)
Randomised trial comparing zoladex∗ with nolvadex∗ plus zoladex in pre-menopausal advanced breast cancer (1992) (2)
Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (2021) (1)
The application of clinical trials to solid tumour management: an introduction. (1977) (1)
Clinical trials symposium. Highlights in development of randomized clinical trials. (1981) (1)
Surgery for early breast cancer (1991) (1)
Abstract GS4-04: Ten year results of the international breast cancer intervention study II (2020) (1)
Clinical trials in breast cancer in Australia and New Zealand (1990) (1)
Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only (1993) (1)
Community-based stroke incidence and case-fatality in a Scottish population - the Scottish Borders Stroke Study (SBSS) (2005) (1)
Non-invasive head-cooling methods and devices (2012) (1)
Internation breast cancer intervention study I: updated side effects analysis (2006) (1)
Abstract PD4-1: Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis (2015) (1)
Optimizing palliative surgical support of cancer patients with visceral obstructions. (1991) (1)
Abstract P1-12-05: Aromatase inhibitor induced musculoskeletal syndrome (AIMSS) in Australian women with early breast cancer: An Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) survey of members of the Breast Cancer Network Australia (BCNA) (2015) (1)
Tamoxifen and Advanced Breast Cancer: An Overview (2002) (1)
P2-12-09: Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study. (2011) (1)
Abstract P2-09-03: Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC (2017) (1)
Adjuvant therapy in breast cancer. (1982) (1)
P2-12-01: Immunohistochemical (IHC) BAG1 Expression Improves the Estimation of Residual Risk (RR) by IHC4 in Postmenopausal Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study. (2011) (1)
Surgery of early breast cancer (1993) (1)
Guidelines for planning clinical trials. (1977) (1)
One year effect of anastrozole and risedronate on bone mineral density: First results from the IBIS-II bone sub-study (2011) (1)
Surgery for early breast cancer. (1990) (1)
Characteristics of studies (2012) (1)
Prevention and treatment trials need different recruitment strategies: Experience from the IBIS 1 prevention trial in Australia and New Zealand. (2004) (1)
Abstract S6-03: Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS) (2016) (1)
Abstract S4-06: HER2 status as predictive marker for AI vs Tam benefit: A TRANS-AIOG meta-analysis of 12129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 (2016) (1)
Prevalence of sleep apnoea, sleepiness and behavioural/emotional disturbances in adults with Down's syndrome in Scotland (2012) (1)
Anastrozole for ductal carcinoma in situ (2003) (1)
Information for members of the public (2012) (1)
Abstract P1-09-06: Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial (2017) (1)
Treating Tumours of the Respiratory System (2003) (0)
Abstract P3-07-01: Prognostic role and impact of multi-clonal ER and PgR expression in ductal carcinomain situ: Results from the UK/ANZ DCIS trial: (2016) (0)
Principles and Practice of“Critical Appraisal” (2003) (0)
Chapter 40. Breast Cancer (2007) (0)
Adjuvant use of anastrozole in breast cancer. Authors' reply (2004) (0)
130: Eight microRNAs as biomarkers for metastatic spread in triple negative breast cancer (2014) (0)
Management of.breast cancer risk — Screening versus prophylaxis (2002) (0)
5001 CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC) (2009) (0)
Breast Cancer Trials of the Ludwig and International Breast Cancer Study Group (1987) (0)
A Randomised Controlled Trial Evaluating a Rehabilitation Complex Intervention for patients following Intensive Care discharge (2016) (0)
Aim and objectives (2012) (0)
Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience: (2015) (0)
The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer (2014) (0)
Oestrogen and breast cancer (1992) (0)
Abstract OT2-04-03: Examining personalized radiation therapy (EXPERT): A randomised phase III trial of adjuvant radiotherapy vs observation in patients with molecularly characterized luminal A breast cancer (2019) (0)
Comment on: Tamoxifen for the prevention of breast cancer : Current status of the national surgical adjuvant breast and bowel project P-1 study. Authors' reply (2006) (0)
Clinical trials and local treatment of early breast cancer. (1992) (0)
Early stopping of clinical trials (Commentary) (2005) (0)
Overweight and breast cancer risk in the International Breast Cancer Intervention studies I and II. (2018) (0)
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. (2011) (0)
Poster Session I: Surgical Aspects (1999) (0)
1099: Improving Staff Communication in the Pediatric Intensive Care Unit Through Multimodal Interventions (2020) (0)
The conditions and incidence: traumatic brain injury and stroke (2012) (0)
Population economics: a survey of recent research. (1983) (0)
10-year results of the International Breast Cancer Intervention Study II (IBIS-II) (2020) (0)
P110 The role of nurse counsellor support groups for women diagnosed with breast cancer at hunter breast screen (1998) (0)
Treating Tumours of the Gastrointestinal Tract (2003) (0)
S19 Controversies in the use of sentinel nodes in the elderly (2007) (0)
Tamoxifen for breast-cancer prevention. Authors' reply (2003) (0)
Considerations for a clinician before supporting a clinical trial. (1981) (0)
The surgery of early breast cancer. (1992) (0)
Meeting abstracts from the Annual Conference on Hereditary Cancers 2016 (2017) (0)
Early breast cancer--an overview of current and future directions. (1987) (0)
P3-14-28: ANZ 0502 NeoGem: A Phase II Trial Evaluating the Efficacy and Safety of Epirubicin and Cyclophosphamide Followed by Docetaxel with Gemcitabine (+ Trastuzumab If HER2 Positive) as Neoadjuvant Chemotherapy for Women with Large Operable or Locally Advanced Breast Carcinoma. (2011) (0)
Impact of Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients With Lymph Node-Negative Breast Cancer: Results on the Effect of Age From the International (2006) (0)
References to head-cooling studies (2012) (0)
Identifying patients with traumatic brain injury in the WardWatcher database (2012) (0)
Biological versus statistical planning of clinical trials. (1981) (0)
Modelling of cost-effectiveness of head cooling (2012) (0)
S20 Chemoprevention of breast cancer: The European and Australian IBIS and other trial experience with aromatase inhibitors (2010) (0)
139O SERUM HER-2/NEU DECLINE PREDICTS IMPROVED RESPONSE TO TRASTUZUMAB-BASED THERAPY (2006) (0)
Timing and severity of prominent side effects of anastrozole and tamoxifen (2008) (0)
EFFECT OF AROMATASE INHIBITION ON BONE DENSITY AND BONE TURNOVER IN HEALTHY POSTMENOPAUSAL WOMEN: RESULTS OF THE INTERNATIONAL BREAST CANCER INTERVENTION STUDY II (IBIS-II) (2014) (0)
Abstract P6-03-03: Tropomyosin-related kinase A is overexpressed in HER2-positive breast cancers (2017) (0)
Letter: Familial male breast cancer. (1976) (0)
Abstract S5-03: Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1) (2017) (0)
THE AUSTRALIA NEW ZEALAND BREAST CANCER TRIALS GROUP: SOME CONTRIBUTIONS TO BREAST CANCER TRIALS (2006) (0)
Breast cancer survivors. -letter- (2008) (0)
Study assessment and data collection form: systematic review of head cooling (version 3) (2012) (0)
The Nisbet Symposium 1986 Early Breast Cancer – An Overview of Current and Future Directions (1987) (0)
Treating Gynaecological Tumours (2003) (0)
FIGURE 15, Kholod 2-F device Photo: RIA Novosti 01.11.1970 (2012) (0)
The expression of Dicer or Drosha is not associated with lymph node metastases in triple negative breast can cer (2013) (0)
Tamoxifen for breast-cancer prevention [3] (multiple letters) (2003) (0)
Surgical Oncology (2003) (0)
Providing services for patients with schizophrenia: In-patient care—-the clinical and economic perspective (1995) (0)
Ad Hoc Reviewers (1991) (1992) (0)
Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer (2014) (0)
Abstract S3-07: 16 year long-term follow-up of the IBIS-I breast cancer prevention trial (2015) (0)
Review protocol (final agreed version December 2008) (2012) (0)
Fine‐needle aspiration cytology in the management of breast disease (1984) (0)
Improving Informed Consent to Clinical Trials: A Pilot of a Decision Aid for Women Invited to Participate in a Breast Cancer Prevention Trial (IBIS-II): 658 (2006) (0)
Systemic adjuvant therapies for early breast cancer: 15‐year results for recurrence and survival (2005) (0)
CORRIGENDUM FOR "Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men". (2018) (0)
Temperature measurement with head cooling (2012) (0)
Progress in cancer therapy from clinical trials. (1979) (0)
FIGURE 27, [1, Rubber helmet; 2, rubber...]. (2012) (0)
Sharing health service capital resources in Scotland. (1980) (0)
Screening for Cancers (2003) (0)
Treating Central Nervous System Tumours (2003) (0)
The College Foundation. (1979) (0)
Preliminary Summary of the Consensus Discussion (2013) (0)
MULTIMODAL THERAPY FOR STAGE-II BREAST CANCER (1977) (0)
10-year analysis of the ATAC trial: wrong conclusion? Reply (2011) (0)
Surgery, kinetics and biological considerations in planning adjuvant therapy protocols. (1990) (0)
Treating Tumours of the Urogenital System (2003) (0)
Treating Cancers of the Eye and Associated Structures (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John F. Forbes?

John F. Forbes is affiliated with the following schools:

University of Southern Denmark
University College London
University of Newcastle
University of Melbourne
University of Limerick
University of Edinburgh
Queen Mary University of London